Kailera Therapeutics prices IPO at $16 per share, offering 39.06 million shares, expecting to raise $625 million.
Quiver AI Summary
Kailera Therapeutics, Inc., a biotechnology company focused on obesity care, has announced the pricing of its initial public offering (IPO) of 39,062,500 shares of common stock at $16.00 per share, aiming to raise approximately $625 million in gross proceeds. The shares will begin trading on the Nasdaq Global Select Market under the ticker symbol "KLRA" on April 17, 2026, with the offering expected to close on April 20, 2026. The company has also provided underwriters the option to purchase an additional 5,859,375 shares. J.P. Morgan, Jefferies, and several other firms are managing the offering, with a registration statement already effective as of April 16, 2026. This announcement does not constitute an offer to sell or a solicitation for purchases of these securities in jurisdictions where it would be unlawful to do so.
Potential Positives
- Kailera Therapeutics successfully priced its initial public offering, raising expected gross proceeds of $625.0 million, which can significantly enhance its financial position and ability to fund future projects.
- The company's shares are set to begin trading on the Nasdaq Global Select Market, elevating its visibility and credibility in the financial market.
- The option granted to underwriters to purchase additional shares indicates strong interest in the offering and potential for further capital raised.
Potential Negatives
- The initial public offering (IPO) pricing at $16.00 per share may indicate a cautious market response, which could affect investor perception of the company's valuation.
- The offering relies entirely on the sale of common stock by Kailera, potentially leading to concerns about the company's existing financial health and sustainability without outside funding.
- The press release does not provide information on the use of proceeds from the IPO, which could create uncertainty among investors about how the funds will be utilized for future growth and development.
FAQ
What is the pricing of Kailera's initial public offering?
Kailera's initial public offering is priced at $16.00 per share for 39,062,500 shares.
When will Kailera's stock begin trading on Nasdaq?
Kailera's common stock is expected to begin trading on the Nasdaq under the ticker symbol “KLRA” on April 17, 2026.
What are the expected gross proceeds from the offering?
The gross proceeds from the offering are expected to be $625.0 million, excluding any underwriters' options.
Who are the underwriters for Kailera's IPO?
The underwriters include J.P. Morgan, Jefferies, Leerink Partners, TD Cowen, and Evercore ISI.
What is the closing date for Kailera's offering?
The offering is expected to close on April 20, 2026, subject to customary closing conditions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the pricing of its initial public offering of 39,062,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares of common stock are being offered by Kailera. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Kailera, are expected to be $625.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. Kailera’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “KLRA” on April 17, 2026. The offering is expected to close on April 20, 2026, subject to the satisfaction of customary closing conditions. In addition, Kailera has granted the underwriters a 30-day option to purchase up to an additional 5,859,375 shares of common stock at the initial public offering price less underwriting discounts and commissions.
J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI are acting as joint book-running managers for the offering. William Blair is acting as lead manager for the offering.
A registration statement on Form S-1 (File No. 333-294690) relating to the offering has been filed with the Securities and Exchange Commission and became effective on April 16, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected] ; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected] ; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected] ; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected] ; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at [email protected] .
This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Contact
Maura Gavaghan
Vice President, Corporate Communications and Investor Relations
[email protected]
